7 documents found, page 1 of 1

Diagnóstico da Doença Renal Crónica em Adultos em Portugal

Publisher Copyright: Copyright © Ordem dos Médicos 2025.; Chronic kidney disease represents a significant public health issue, affecting approximately 9.8% of the adult population in Portugal. Despite this figure, early diagnosis of this disease in high-risk groups remains limited. Although only two parameters are essential for its diagnosis – estimated glomerular filtration rate (eGFR) and albuminuria – in Por...

Finerenone cardiovascular and kidney outcomes by age and sex

Objectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex. Design FIDELITY post hoc analysis; median follow-up of 3 years. Setting FIDELITY: a prespecified analysis of the FIDELIO-DKD and FIGARO-DKD trials. Participants Adults with type 2 diabetes and chronic kidney dise...

Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospi...

Funding Information: Medical writing and editorial support were provided by Laura Watts, PhD, of Lumanity Communications Inc. (Yardley, Pennsylvania, USA), and were funded by Gilead Sciences. Investigators thank the patients and their families for their participation This work was supported by Gilead Sciences. Publisher Copyright: © The Author(s) 2024.; Background. Few antiviral therapies have been studied in p...

Síndrome de Wunderlich num doente em hemodiálise

Wunderlich syndrome in a patient on hemodialysis

Funding Information: R. Birne reports the following: employed by Diaverum; research funding from Gilead, Bayer, and Boehringer; member in advisory board of Bayer and Boehringer; and member of the speakers bureau of AstraZeneca, Bayer, Boehringer, MSD and Bial. M. Roxo reports the following: employed by Fresenius Medical Care.

Insulin

This work was supported by “Fundação para a Ciência e a Tecnologia” – FCT to AP (PD/BD/136887/2018); MJM (PD/BD/114256/2016), MPM (PTDC/DTP-EPI/0207/2012), DOB e MPM (PTDC/BIM-MET/2115/2014); iNOVA4Health (UIDB/Multi/04462/2020), by the European Commission Marie Skłodowska -Curie Actions H2020 (grant agreements nos. 722619 and 734719), and by the Sociedade Portuguesa de Diabetologia.; Kidney function in metabol...

Efeito da empagliflozina para além do controlo glicémico

The prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D. This article explores the various trials already performed and under development in this field, with particular focus on the EMPA‐REG OUTCOME trial. In this trial, empagliflozin, a sodium‐glucose co‐transporter 2 ...